96 Tests PN: B311183

Components:

45x Ab-conjugated beads (S4P6 - Rat IL-11 Ab-bead). PN: B311183A. One vial containing 100 µL of anti-rat IL-11 conjugated to AimPlex Bead S4P6.

25x Biotin-detection Ab (Rat IL-11 Biotin-dAb). PN: B311183B. One vial containing 100 µL of biotinylated anti-rat IL-11.

Lyophilized Standard Mix - Rat IL-11, PN: B311183S. One vial containing lyophilized IL-11.

Application: Optimal antibody pair and antigen standard for assaying Rat IL-11. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

Interleukin 11 (Accession Q99MF5) is a member of the IL-6 cytokine family. IL-11 activity has been observed in hematopoietic cells, the tissues of the central nervous system, and in the gastrointestinal organs. In concert with IL-11Rα, IL-11 is believed to activate downstream signaling pathways for the regulation of platelet maturation, adipogenesis, neurogenesis, and osteoclastogenesis, as well as placentation. IL-11 can increase the tumorigenic ability of cells. As over expression is associated with many types of cancer, inhibiting its signaling pathway may be effective in treating cancer. Recombinant IL-11 is currently on the market for cancer patients to prevent extreme thrombocytopenia.

References:

  1. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994; 93(4) 1516-1524. Doi: 10.1172/JCI117130.

  2. Putoczki TL, Ernst M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy. 2015; 7(4): 441-53. Doi: 10.221/imt.15.17.

  3. Sitaraman SV, Gewirtz AT. Oprelvekin. Genetics Institute. Curr Opin Investig Drugs. 2001. 2(10): 1395-400. PMID: 11890354.

  4. Xu DH, Zhu Z, Wakefield MR, Xiao H, Bai Q, Fang Y. The role of IL-11 in immunity and cancer. Cancer Lett. 2016; 373(2): 156-63. Doi: 10.1016/j.canlet.2016.01.004.